Bavarian Nordic climbs on Prostvac data

Bavarian Nordic A/S (CSE:BAVA) jumped DKK22.50 (12%) to DKK213.50 after reporting survival data from a Phase I trial of Prostvac in combination with Yervoy ipilimumab from Bristol-Myers Squibb Co. (NYSE:BMY) in patients with metastatic castration-resistant prostate cancer (mCRPC).

In a National Cancer Institute-funded study of 30 mCRPC patients treated with Prostvac plus escalating doses of Yervoy, the median OS for all dose cohorts was 31.3 months, compared to the predicted median OS of 18.5 months. Patients who received 10 mg/kg of Yervoy had a median OS of 37.2 months, and 20% remained alive at 80 months. At the time of enrollment, docetaxel was the only FDA-approved treatment to improve OS in mCRPC patients. Newer drugs Xtandi enzalutamide and Zytiga abiraterone have since eclipsed docetaxel as standard of care, after androgen-deprivation therapies have failed. ...